Search results
Showing 1081 to 1090 of 1090 results for criteria
Four digital technologies that can help children and young people with mild to moderate symptoms of anxiety or low mood have been recommended for use in the NHS.
Nine treatment options to be made available for adults with depression or an anxiety disorder
Six digitally enabled therapies for adults with anxiety disorders and three for adults with depression have been recommended for use in the NHS.
Seven technologies recommended to help people with non-specific low back pain
People with non-specific low back pain could be offered apps to help them manage their condition after seven digital technologies were recommended in draft guidance.
Digital services to enable easier access to weight management support
Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England
Two technologies to provide digital services for people with COPD
More people with chronic obstructive pulmonary disease (COPD) could soon access rehabilitation programmes after draft guidance from NICE conditionally recommended two technologies to provide digital services to NHS patients.
Adapted shoes recommended for people with severe osteoarthritis
People with osteoarthritis who are eligible for knee surgery could be offered specially adapted shoes to help with their painful and stiff knees following a draft recommendation by NICE.
New treatment option for adults with obesity and non-diabetic hyperglycaemia
All eligibility criteria must be met for Liraglutide to be offered.
More people could be offered genetic testing for genes linked to ovarian cancer
A new draft NICE guideline for inherited ovarian cancer published today (15 September 2023), recommends more people are tested for genes linked to ovarian cancer.
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.
More people with rare genetic disorder eligible for nusinersen
Following a review of data collected as part of the Managed Access Agreement, more people with spinal muscular atrophy (SMA) are to benefit from nusinersen.